Drug intelligence / Profile preview

ETH-201

Development stage: Preclinical
Lead developer: Shengke Pharmaceuticals Ltd.

Overview

**ETH-201** is a preclinical cardiovascular-disease therapeutic candidate developed by Shengke Pharmaceuticals. Public drug-intelligence records identify ETH-201 as an inhibitor of proprotein convertase subtilisin/kexin type 9, a lipid-regulation target relevant to lowering circulating low-density lipoprotein cholesterol. Shengke Pharmaceuticals publicly lists ETH-201 in its development pipeline. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/ed88381a020d4dc5b6c86061a3f80863))

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on ETH-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETH-201.

Explore the full profile